These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 26403941)

  • 61. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
    Hartmann JT; Haap M; Kopp HG; Lipp HP
    Curr Drug Metab; 2009 Jun; 10(5):470-81. PubMed ID: 19689244
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
    Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
    Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
    [No Abstract]   [Full Text] [Related]  

  • 63. Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
    Imano H; Kato R; Ijiri Y; Hayashi T
    Toxicol In Vitro; 2021 Mar; 71():105063. PubMed ID: 33271325
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
    Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
    Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
    Wang S; Yang Z; Wang Z
    Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
    Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
    Sonpavde G; Je Y; Schutz F; Galsky MD; Paluri R; Rosenberg JE; Bellmunt J; Choueiri TK
    Crit Rev Oncol Hematol; 2013 Jul; 87(1):80-9. PubMed ID: 23317774
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
    Keil C; Götze L; Olbert P; Hofmann R; Nockher WA; Hegele A
    Urologe A; 2015 Jun; 54(6):811-8. PubMed ID: 25503897
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Management of sunitinib-associated adverse events].
    Kanda H; Masui S; Yamada Y; Arima K; Sugimura Y
    Hinyokika Kiyo; 2012 Nov; 58(11):639-46. PubMed ID: 23254793
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions.
    Yokoyama H; Shioyama W; Shintani T; Maeda S; Hirobe S; Maeda M; Sakata Y; Fujio Y
    Int Heart J; 2021; 62(6):1297-1304. PubMed ID: 34853223
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.
    Iacovelli R; Palazzo A; Procopio G; Santoni M; Trenta P; De Benedetto A; Mezi S; Cortesi E
    Br J Clin Pharmacol; 2014 Jun; 77(6):929-38. PubMed ID: 23981115
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bone metastases and age are associated with earlier dose reductions in metastatic clear-cell renal cell carcinoma patients treated with angiogenesis inhibitors.
    Haaker L; De Meue E; Wildiers H; Verbiest A; Dumez H; Lerut E; Pans S; Albersen M; Beuselinck B
    Acta Clin Belg; 2019 Dec; 74(6):414-423. PubMed ID: 30497350
    [No Abstract]   [Full Text] [Related]  

  • 73. Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
    Liu J; Nicum S; Reichardt P; Croitoru K; Illek B; Schmidinger M; Rogers C; Whalen C; Jayson GC
    Gynecol Oncol; 2018 Jul; 150(1):173-179. PubMed ID: 29627080
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.
    Klein Hesselink EN; Steenvoorden D; Kapiteijn E; Corssmit EP; van der Horst-Schrivers AN; Lefrandt JD; Links TP; Dekkers OM
    Eur J Endocrinol; 2015 May; 172(5):R215-25. PubMed ID: 25572389
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1063-73. PubMed ID: 24927771
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin.
    Kotecki N; Penel N
    Curr Opin Oncol; 2016 Sep; 28(5):437-40. PubMed ID: 27428364
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.
    Goldman A; Bomze D; Dankner R; Fourey D; Boursi B; Arad M; Maor E
    Target Oncol; 2021 Jul; 16(4):471-483. PubMed ID: 33970401
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs.
    Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
    J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group.
    Sodergren SC; White A; Efficace F; Sprangers M; Fitzsimmons D; Bottomley A; Johnson CD
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):35-46. PubMed ID: 24495942
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.
    Vigarios E; Epstein JB; Sibaud V
    Support Care Cancer; 2017 May; 25(5):1713-1739. PubMed ID: 28224235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.